Charles Riv­er Labs forks over $380M cash for cell ther­a­py play­er; Ax­some soars on PhI­II de­pres­sion read­out

→ Cell ther­a­py R&D is hot, and Charles Riv­er Labs $CRL knows it. The CRO is pay­ing $380 mil­lion to ac­quire HemaCare, a com­pa­ny that pro­vides ma­te­r­i­al and ser­vices for com­pa­nies de­vel­op­ing off-the-shelf and per­son­al­ized cell ther­a­pies. Charles Riv­er says it’s de­vel­op­ing a turnkey ser­vice for cell ther­a­py de­vel­op­ers and man­u­fac­tur­ers.

“Cell and gene ther­a­pies are im­por­tant new modal­i­ties, with an es­ti­mat­ed 10 to 20 new prod­uct ap­provals per year with­in five years,” notes Charles Riv­er CEO James Fos­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER